HomeComparePPBI vs ABBV

PPBI vs ABBV: Dividend Comparison 2026

PPBI yields 5.39% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PPBI wins by $886.2K in total portfolio value· pulled ahead in Year 2
10 years
PPBI
PPBI
● Live price
5.39%
Share price
$24.49
Annual div
$1.32
5Y div CAGR
50.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.5K
Annual income
$613,145.25
Full PPBI calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PPBI vs ABBV

📍 PPBI pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPPBIABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PPBI + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PPBI pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PPBI
Annual income on $10K today (after 15% tax)
$458.15/yr
After 10yr DRIP, annual income (after tax)
$521,173.46/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, PPBI beats the other by $500,117.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PPBI + ABBV for your $10,000?

PPBI: 50%ABBV: 50%
100% ABBV50/50100% PPBI
Portfolio after 10yr
$545.4K
Annual income
$318,958.51/yr
Blended yield
58.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PPBI
Analyst Ratings
6
Buy
8
Hold
Consensus: Hold
Price Target
$32.67
+33.4% upside vs current
Range: $26.00 — $41.00
Altman Z
-0.6
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PPBI buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPPBIABBV
Forward yield5.39%3.06%
Annual dividend / share$1.32$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR50.5%40.6%
Portfolio after 10y$988.5K$102.3K
Annual income after 10y$613,145.25$24,771.77
Total dividends collected$927.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$32.67$256.15

Year-by-year: PPBI vs ABBV ($10,000, DRIP)

YearPPBI PortfolioPPBI Income/yrABBV PortfolioABBV Income/yrGap
1$11,511$811.19$11,550$430.00$39.00ABBV
2← crossover$13,630$1,313.39$13,472$627.96+$158.00PPBI
3$16,772$2,187.43$15,906$926.08+$866.00PPBI
4$21,732$3,785.84$19,071$1,382.55+$2.7KPPBI
5$30,153$6,899.67$23,302$2,095.81+$6.9KPPBI
6$45,729$13,465.16$29,150$3,237.93+$16.6KPPBI
7$77,652$28,722.70$37,536$5,121.41+$40.1KPPBI
8$151,691$68,603.25$50,079$8,338.38+$101.6KPPBI
9$350,806$188,496.65$69,753$14,065.80+$281.1KPPBI
10$988,508$613,145.25$102,337$24,771.77+$886.2KPPBI

PPBI vs ABBV: Complete Analysis 2026

PPBIStock

Pacific Premier Bancorp, Inc. operates as the bank holding company for Pacific Premier Bank that provides banking services to businesses, professionals, real estate investors, and non-profit organizations. The company accepts deposit products, such as checking, money market, and savings accounts; and certificates of deposit. Its loan portfolio includes commercial real estate owner and non-owner-occupied, multifamily, construction and land, franchise real estate secured, small business administration (SBA), and SBA paycheck protection program loans; revolving lines or credit, term loans, seasonal loans, and loans secured by liquid collateral; one-to-four family and home equity lines of credit loans; and savings account secured loans and auto loans. The company also offers cash management, electronic banking, treasury management, and online bill payment services. It operates 61 full-service depository branches located in Arizona, California, Nevada, Oregon, and Washington. Pacific Premier Bancorp, Inc. was founded in 1983 and is headquartered in Irvine, California.

Full PPBI Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PPBI vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PPBI vs SCHDPPBI vs JEPIPPBI vs OPPBI vs KOPPBI vs MAINPPBI vs JNJPPBI vs MRKPPBI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.